Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix

Anti-Cancer Drugs

Volumn 7, Issue 4, 1996, Pages 398-401

  Kudelka, A P ^a   Verschraegen, C F ^a   Levy, T ^a,b   Edwards, C L ^a   Fishman, A ^b   Freedman, R S ^a   Kaplan, A ^b   Kieback, D G ^b   Mante, R ^a   Ende, K ^a   Steger, M ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cervix cancer; Docetaxel; Granulocyte colony stimulating factor

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ALLERGIC REACTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; FEMALE; GRANULOCYTOPENIA; HUMAN; HUMAN TISSUE; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NEUROPATHY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION; UTERINE CERVIX CANCER; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; TAXOIDS; UTERINE CERVICAL NEOPLASMS;

EID: 8944249284     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199606000-00004     Document Type: Article

References (24)

1. Devesa SS, Silverman DT, Young JL, et al. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987; 79: 701-70.
2. Parkin DM, Muir CS, Whelan SL, et al. eds. Cancer incidence in five continents. Lyon: International Agency for Research on Cancer 1992; VI.
3. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995; 45: 8-30.
4. Thigpen T, Vance RB, Khansur T. Carcinoma of the uterine cervix: current status and future directions. Semin Oncol 1994; 21 (suppl 2): 43-54.
5. Bonomi P, Blessing J, Stehman F, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985; 3: 1079-85.
6. Coleman R, Jarper P, Gallagher C, et al. A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix. Cancer Chemother Pharmacol 1986; 8: 280-3.
7. Takeuchi S, Noda K, Yakushiji M, et al. Late phase II study of CPT-11, topoisomerase I inhibitor, in advanced cervical carcinoma. Proc Am Soc Clin Oncol 1992; 11: 224.
8. Kavanagh JJ, Kudelka AP, Edwards CL, et al. CPT-11 (Irinotecan): phase II study in refractory squamous cell carcinoma of the cervix. Proc Am Ass Cancer Res 1995, 35: 34.
9. Wall ME, Wani MC. Paclitaxel: from discovery to clinic. In: George GI, Chen TT, Ojima I, Vyas DM, eds. ACS Symposium-in-Print. Taxane anticancer agents: basic science and current status 1995; 583: 18-30.
10. Schiff PB, Fant J, Horowitz S. Promotion of microtubule assembly in vitro by taxol. B Nature 1979; 22: 665-7.
11. Pazdur R, Kudelka AP, Kavanagh JJ, et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19: 351-86.
12. Holmes FA, Kudelka AP, Kavanagh JJ, et al. Current status of clinical trials with paclitaxel and docetaxel. In: George GI, Chen TT, Ojima I, Vyas DM, eds. ACS Symposium-in-Print. Taxane anticancer agents: basic science and current status 1995; 583: 31-57.
13. Forastiere AA, Use of paclitaxel (Taxol) in squamous cell carcinoma of the head and neck (review). Semin Oncol 1993; 20: 56-60.
14. Thornton D, Singh K, Putz B, et al. A phase II trial of taxol in squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1994; 13: A933.
15. Ajani JA, Ilson DH, Daugherty K, et al. Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-91.
16. Ringel I, Horwitz SB. Studies with Taxotere (RP 56976); a semisynthic analog of taxol. J Natl Cancer Inst 1991; 83: 288-91.
17. Catimel G, Verweij J, Mattijssen V. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 533-1
18. Gehan EA. Number of patients required in a new drug trial. J Chron Dis 1961; 346-353.
19. Lopez A, Kudelka AP, Edwards CL. Carcinoma of the uterine cervix. In: Pazdur R, Huntington PRR, eds. Medical oncology: a comprehensive review. 1995; 22: 393-405.
20. Thigpen T, Vance RB, Khansur T. The platinum compounds and paclitaxel in the management of carcinomas of the endometrium and uterine cervix. Semin Oncol 1995; 22: 66-75.
21. 2 administered intravenously (IV) over 3 h every 21 days with G-CSF support. Proc Am Soc Clin Oncol 1996; in press.
22. Bicher A, Kohn E, Sarosy G, et al. The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor. Anti-Cancer Drugs 1993; 4: 141-8.
23. Choy H, Rodriguez F, Wilcox B, et al. Radiation-sensitizing effects of taxotere (RP 56976) (meeting abstract). Proc Ann Meet Ass Cancer Res 1992; 33: A2991.
24. Rosenthal DI, Close LG, Lucci JA, et al. Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors. Semin Oncol 1995; 22 (4 suppl 9): 13-7.